Cullinan Therapeutics (CGEM) Income from Continuing Operations (2020 - 2026)

Cullinan Therapeutics' Income from Continuing Operations history runs 7 years deep, the most recent figure standing at 52352000.0 for Q1 2026.

• In Q1 2026, Income from Continuing Operations fell 7.47% year-over-year to 52352000.0; the TTM figure through Mar 2026 stood at 224795000.0 (up 28.16% YoY), while the FY2025 annual figure was 219879000.0, down 66.39% from the prior year.
• Income from Continuing Operations for Q1 2026 stood at 52352000.0, down from 50653000.0 in the prior quarter.
• The five-year high for Income from Continuing Operations was 174065000.0 in Q2 2022, with the low at 178475000.0 in Q4 2024.
• The 5-year median for Income from Continuing Operations is 45002000.0 (2024), against an average of 38390529.41.
• Peak annual rise in Income from Continuing Operations reached 1158.85% in 2022, while the deepest fall reached 1008.53% in 2022.
• Cullinan Therapeutics' Income from Continuing Operations stood at 27046000.0 in 2022, then plunged by 98.86% to 53785000.0 in 2023, then tumbled by 231.83% to 178475000.0 in 2024, then surged by 71.62% to 50653000.0 in 2025, then slipped by 3.35% to 52352000.0 in 2026.
• Business Quant data shows CGEM's Income from Continuing Operations at 52352000.0 in Q1 2026, 50653000.0 in Q4 2025, and 51740000.0 in Q3 2025.